Purinergic receptors and pain 

Pain management remains a significant challenge, as current medications, particularly for some types of pain such as neuropathic pain, often show limited efficacy or cause severe side effects, emphasizing the urgent need for new safer, effective and non-addictive treatments. This highlights the importance of developing innovative analgesics with novel mechanisms of action.

In this context, strong evidence supports the involvement of purinergic receptors, particularly P2X3 and P2X4, in pain modulation. Our primary objective is to design and develop novel drug candidates and research tools that target these receptors, ultimately providing new and alternative solutions for pain management.

 

 

Antiviral agents

 

Viral outbreaks, like the COVID-19 pandemic, have highlighted the urgent need for more effective antiviral strategies. Current treatment often struggle with drug resistance, limited spectrum of activity, and adverse effects, making it crucial to develop new therapeutic approaches.

Our research aims to design and develop novel antiviral agents and molecular tools that target essential viral mechanisms, contributing to the advancement of next-generation antiviral therapies. Our primary focus is on poxviruses and coronaviruses.